Literature DB >> 9013377

Physical aspects of dexibuprofen and racemic ibuprofen.

G Leising1, R Resel, F Stelzer, S Tasch, A Lanziner, G Hantich.   

Abstract

This article presents a comparative study of ibuprofen materials in their solid state. Ibuprofen crystallizes into two different structures for the S(+) enantiomer (dexibuprofen) and racemic ibuprofen. The crystal structure of ibuprofen, its optical absorption and photoluminescence, and the thermodynamic results (melting point and heat of fusion) are discussed. From these physicochemical properties, the authors conclude that dexibuprofen, which is the most active species pharmaceutically, and racemic ibuprofen are inherently different solid-state materials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013377

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

Review 1.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

2.  The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection.

Authors:  Jong Seo Yoon; Dae-Chul Jeong; Jae-Won Oh; Keun Young Lee; Hyun Seung Lee; Young Yull Koh; Jin Tack Kim; Jin Han Kang; Joon Sung Lee
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

3.  Dexibuprofen: pharmacology, therapeutic uses and safety.

Authors:  S T Kaehler; W Phleps; E Hesse
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

4.  S(+)-ibuprofen (dexibuprofen)--Excellent tolerance has not to be combined with poor clinical efficacy.

Authors:  A Zohmann; R Hawel; G Klein; W Kullich; G Lötsch
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 5.093

Review 5.  Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations.

Authors:  Anna Gliszczyńska; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.